PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $11.00.
Several research analysts recently commented on the company. Oppenheimer assumed coverage on PolyPid in a research report on Tuesday, October 27th. They set an “outperform” rating and a $10.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of PolyPid in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of PolyPid from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Craig Hallum set a $12.00 price target on shares of PolyPid in a report on Wednesday, July 22nd.
Check Out Our Latest Analysis on PolyPid
PolyPid Stock Up 0.6%
Shares of PYPD opened at $5.42 on Tuesday. PolyPid has a 12-month low of $3.50 and a 12-month high of $5.84. The firm has a market capitalization of $103.41 million, a PE ratio of -3.66 and a beta of 1.38. The stock’s fifty day simple moving average is $5.20 and its 200-day simple moving average is $4.73.
PolyPid (NASDAQ:PYPD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.03. Analysts anticipate that PolyPid will post -0.44 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of PYPD. B. Riley Wealth Advisors Inc. grew its holdings in shares of PolyPid by 32.7% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after purchasing an additional 4,955 shares during the last quarter. Connective Capital Management LLC purchased a new position in shares of PolyPid during the second quarter valued at approximately $343,000. HighTower Advisors LLC purchased a new stake in PolyPid in the second quarter worth $56,000. AXQ Capital LP bought a new stake in PolyPid in the second quarter valued at $87,000. Finally, Symmetry Peak Management LLC purchased a new position in PolyPid during the 2nd quarter valued at $512,000. 26.47% of the stock is owned by institutional investors.
About PolyPid
PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.
PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix.
Read More
- Five stocks we like better than PolyPid
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
